Genmab — Juli 2017
-
fra JNJ's hjemmeside, inkl. tallene http://www.investor.jnj.com/releasedetail.cfm?ReleaseID=1033438
-
Strong growth in new products include DARZALEX
(daratumumab), for the treatment of patients with multiple myeloma -
jeg forstår ikke helt US actual tallet ifht recepttallene. Med en flad udvikling i juni burdre US omsætningen have været over usd 230m
-
Hvis man regner med 17,25% stigning ligeledes i de næste 2 kvartaler. Så kommer Q3 på 350, Q4 på 410 og hele året på 1314.
-
hvis recepttallene for april/maj (71,1m / 80,5m) er korrekte, så er US omsætningen i juni usd 60,4m
-
Stigningstakten skal forøges for at tilfredsstille markedet!
-
-
Copenhagen, Denmark; July 18, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 299 million in the second quarter of 2017. Net sales were USD 212 million in the U.S. and USD 87 million in the rest of the world. Genmab will receive royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize DARZALEX.
-
tallene i morgen er uinteressante da de er fra juni. tallene i dag indeholder også juni
-
Men alle der har en lommeregner, kan da nu udregne Symphony Health tallet i morgen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind